Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lessons from the withdrawal of rofecoxib.

× No keyword cloud information.

11 in total

1. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

Authors: Peter Jüni; Anne W S Rutjes; Paul A Dieppe
Journal: BMJ Date: 2002-06-01

2. A model for the future conduct of pharmacovigilance.

Authors: Patrick C Waller; Stephen J W Evans
Journal: Pharmacoepidemiol Drug Saf Date: 2003 Jan-Feb Impact factor: 2.890

3. Medical journals and pharmaceutical companies: uneasy bedfellows.

Authors: Richard Smith
Journal: BMJ Date: 2003-05-31

Review 4. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs.

Authors: Paul Dieppe; Christopher Bartlett; Peter Davey; Lesley Doyal; Shah Ebrahim
Journal: BMJ Date: 2004-07-03

Review 5. Older people should NOT be prescribed 'coxibs' in place of conventional NSAIDs.

Authors: Peter Jüni; Paul Dieppe
Journal: Age Ageing Date: 2004-03 Impact factor: 10.668

6. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts.

Authors: S Kargman; S Charleson; M Cartwright; J Frank; D Riendeau; J Mancini; J Evans; G O'Neill
Journal: Gastroenterology Date: 1996-08 Impact factor: 22.682

7. Fatal cholestatic jaundice in elderly patients taking benoxaprofen.

Authors: H M Taggart; J M Alderdice
Journal: Br Med J (Clin Res Ed) Date: 1982-05-08

Review 8. Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors: D Mukherjee; S E Nissen; E J Topol
Journal: JAMA Date: 2001 Aug 22-29 Impact factor: 56.272

9. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study.

Authors: Deborah Layton; Jane Riley; Lynda V Wilton; Saad A W Shakir
Journal: Br J Clin Pharmacol Date: 2003-02 Impact factor: 4.335

10. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245

35 in total

Review 1. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials.

Authors: Jan Magnus Bjordal; Anne Elisabeth Ljunggren; Atle Klovning; Lars Slørdal
Journal: BMJ Date: 2004-11-23

2. Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs.

Authors: Lucien Abenhaim
Journal: BMJ Date: 2004-12-04

3. Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten.

Authors: Godfrey Oakley
Journal: BMJ Date: 2004-12-04

4. What if Derek Willoughby were right? Cyclo-oxygenase is an anti-inflammatory enzyme.

Authors: D R Blake; N Shenker; H Cohen; C R Stevens
Journal: Inflammopharmacology Date: 2005 Impact factor: 4.473

5. Sentinel systems are needed for long term adverse drug reactions.

Authors: Torbjörn Callréus
Journal: BMJ Date: 2005-01-29

6. COX 2 inhibitors, traditional NSAIDs, and the heart.

Authors: Peter Jüni; Stephan Reichenbach; Matthias Egger
Journal: BMJ Date: 2005-06-11

Review 7. Using recovery modalities between training sessions in elite athletes: does it help?

Authors: Anthony Barnett
Journal: Sports Med Date: 2006 Impact factor: 11.136

8. The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland.

Authors: D Williams; M Singh; C Hind
Journal: Br J Clin Pharmacol Date: 2006-09 Impact factor: 4.335

9. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.

Authors: C J Hawkey; G M Hawkey; S Everitt; M M Skelly; W A Stack; D Gray
Journal: Br J Clin Pharmacol Date: 2006-06 Impact factor: 4.335

10. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.

Authors: Maribel Salas; Michelle Martin; Maria Pisu; Erin McCall; Alvaro Zuluaga; Stephen P Glasser
Journal: Pharmaceut Med Date: 2008-03-01